3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High
This is not an exhaustive list.
Johnson & Johnson (NYSE: JNJ) is currently performing exceptionally well, with its stock trading near record highs. Despite this strong performance, the company still presents an attractive investment opportunity for those with a long-term perspective. Here are three key reasons why investors should consider adding Johnson & Johnson to their portfolios:
Firstly, while Johnson & Johnson faces challenges in its core Innovative Medicine business, it has diversified its product portfolio across various therapeutic areas. This diversification helps mitigate risks associated with competition and government-driven drug price negotiations, ensuring the company's steady sales and earnings growth.
Secondly, Johnson & Johnson's robust research and development pipeline demonstrates its ability to consistently launch innovative new products. This pipeline strength gives investors confidence that the company can continue to generate revenue and earnings growth in the future, even amidst current challenges.
Lastly, Johnson & Johnson's financial results have been strong this year, leading to its shares trading close to all-time highs. Even at these elevated levels, investing in the company remains justified for long-term investors, as its diversified product lineup and innovative pipeline position it well for continued success.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
